(Total Views: 562)
Posted On: 05/13/2020 10:33:05 PM
Post# of 155808
I continue to be long Cytodyn.
There is much to be excited about, but because I have been burned before, there is no proof till the trials w/ control are complete. The data I am challenged by at this time are the results of the 20 severe CA EINDs. Two died so that's 10% mortality which matches the control and Remdesivir study results. I know these 20 EIND patients were likely not screened and filtered like those in the Remdesivir study, however, the Remdesivir study was for patients classified as "severe."
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease.
Does anyone have knowledge of the Leronlimab severe to Remdesivir "severe" patients?
Thanks.
There is much to be excited about, but because I have been burned before, there is no proof till the trials w/ control are complete. The data I am challenged by at this time are the results of the 20 severe CA EINDs. Two died so that's 10% mortality which matches the control and Remdesivir study results. I know these 20 EIND patients were likely not screened and filtered like those in the Remdesivir study, however, the Remdesivir study was for patients classified as "severe."
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease.
Does anyone have knowledge of the Leronlimab severe to Remdesivir "severe" patients?
Thanks.
(1)
(0)
